In late September, the U.S. Food and Drug Administration (FDA) approved Egetis’ orphan drug Emcitate (tiratricol) for the treatment of peripheral thyrotoxicosis in adults and children with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. It became the first FDA-approved treatment for the rare disorder in the United States.
Egetis sells FDA voucher for 190 million dollars
Swedish biotech Egetis Therapeutics is selling the priority review voucher it recently received following the U.S. approval of its drug Emcitate. The price tag is USD 190 million, half of which will go to the company.
Advertisement
BREAKING